CN115209919B - 慢性心衰的治疗或预防方法 - Google Patents

慢性心衰的治疗或预防方法 Download PDF

Info

Publication number
CN115209919B
CN115209919B CN202180021810.3A CN202180021810A CN115209919B CN 115209919 B CN115209919 B CN 115209919B CN 202180021810 A CN202180021810 A CN 202180021810A CN 115209919 B CN115209919 B CN 115209919B
Authority
CN
China
Prior art keywords
compound
heart failure
acid
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180021810.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN115209919A (zh
Inventor
大熊千寻
佐野龙平
富本大介
中根由富
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CN115209919A publication Critical patent/CN115209919A/zh
Application granted granted Critical
Publication of CN115209919B publication Critical patent/CN115209919B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180021810.3A 2020-03-19 2021-03-18 慢性心衰的治疗或预防方法 Active CN115209919B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-048798 2020-03-19
JP2020048798 2020-03-19
PCT/JP2021/011003 WO2021187548A1 (ja) 2020-03-19 2021-03-18 慢性心不全の治療又は予防方法

Publications (2)

Publication Number Publication Date
CN115209919A CN115209919A (zh) 2022-10-18
CN115209919B true CN115209919B (zh) 2024-12-31

Family

ID=77770987

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021810.3A Active CN115209919B (zh) 2020-03-19 2021-03-18 慢性心衰的治疗或预防方法

Country Status (10)

Country Link
US (1) US20230321044A1 (https=)
EP (1) EP4122495A4 (https=)
JP (2) JPWO2021187548A1 (https=)
KR (1) KR20220156574A (https=)
CN (1) CN115209919B (https=)
AU (1) AU2021237149A1 (https=)
BR (1) BR112022018396A2 (https=)
CA (1) CA3175131A1 (https=)
MX (1) MX2022011490A (https=)
WO (1) WO2021187548A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020343585B2 (en) * 2019-09-04 2026-02-05 Shionogi & Co., Ltd. Chronic kidney disease treatment or prevention method
MX2022002683A (es) * 2019-09-04 2022-04-07 Japan Tobacco Inc Metodo terapeutico o profilactico para diabetes usando medicamentos combinados.
WO2023210634A1 (ja) * 2022-04-28 2023-11-02 国立大学法人東海国立大学機構 拡張障害を伴う心不全の治療用医薬組成物
WO2025249555A1 (en) * 2024-05-31 2025-12-04 Japan Tobacco Inc. Method for treating or preventing hypertrophic cardiomyopathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200735880A (en) * 2006-01-27 2007-10-01 Sankyo Co Medicinal compositions for preventing or treating heart failure
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
CN110066302B (zh) * 2018-01-23 2022-12-27 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其用途
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
MX2020010433A (es) * 2018-04-04 2020-10-28 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.
MX2022002683A (es) * 2019-09-04 2022-04-07 Japan Tobacco Inc Metodo terapeutico o profilactico para diabetes usando medicamentos combinados.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice;Yohei Sawa 等;Journal of Pharmacological Sciences;20191107;第142卷;摘要、第16页、第21-22页 *
Yohei Sawa 等.Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice.Journal of Pharmacological Sciences.2019,第142卷摘要、第16页、第21-22页. *

Also Published As

Publication number Publication date
BR112022018396A2 (pt) 2022-11-08
KR20220156574A (ko) 2022-11-25
EP4122495A1 (en) 2023-01-25
EP4122495A4 (en) 2024-03-27
CN115209919A (zh) 2022-10-18
WO2021187548A1 (ja) 2021-09-23
CA3175131A1 (en) 2021-09-23
MX2022011490A (es) 2022-10-07
US20230321044A1 (en) 2023-10-12
AU2021237149A1 (en) 2022-10-06
JP2026050471A (ja) 2026-03-19
JPWO2021187548A1 (https=) 2021-09-23

Similar Documents

Publication Publication Date Title
CN115209919B (zh) 慢性心衰的治疗或预防方法
JP6930991B2 (ja) 血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤
US20210100805A1 (en) Combination therapy for treating malignancies
KR102924995B1 (ko) 악성종양의 치료 방법
JP4049477B2 (ja) 副作用軽減剤
US20020022627A1 (en) Inhibition of cyclooxygenase-2activity
JP2015518888A (ja) 腫瘍疾患を治療するための１７−アルファ−ヒドロキシラーゼ（ｃ１７，２０−リアーゼ）インヒビターと特定のｐｉ−３ｋインヒビターとの組み合わせ
EP2568982B1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
JP2016504286A (ja) 肺動脈高血圧症及び肺障害の治療に使用するための１，３‐ジヒドロイミダゾール‐２‐チオン誘導体
EP3851103A1 (en) Therapeutic or prophylactic agent for chronic kidney disease containing pyrazole-amide compound
EP3773565A1 (en) Deuterated imidazolidinedione compounds and their uses
HK40077878A (en) Treatment or prevention method for chronic heart failure
AU2002328569B2 (en) Medicinal compositions containing angiotensin II receptor antagonist
WO2025166537A1 (en) Methods of treatment using an ezh2 modulator
US20060094731A1 (en) New medicament
KR100222627B1 (ko) 앙기오텐신-ii 수용체 길항제 및 칼슘 채널 차단제의 신규한 조성물
KR20220162456A (ko) 고혈압을 동반한 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물
HK40047721A (en) Therapeutic or prophylactic agent for chronic kidney disease containing pyrazole-amide compound
KR20070026443A (ko) 허혈성 순환기 질환의 예방 및/또는 치료를 위한 약제
JP2003034649A (ja) 心臓機能障害の改善剤または予防剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant